886372-05-0

Basic information

• Product Name: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER
• Synonyms: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER;4-Chloro-6-methyl-3-pyridinecarboxylic acid methyl ester
• CAS NO: 886372-05-0
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.60762
• Mol File: 886372-05-0.mol

Chemical Properties

• Boiling Point: 242.7 °C at 760 mmHg
• Flash Point: 100.6 °C
• Appearance: /
• Density: 1.247 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(886372-05-0)
• EPA Substance Registry System: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(886372-05-0)

Safety Data

• Hazardous Substances Data: 886372-05-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activity. It plays a crucial role in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER is utilized as a precursor in the production of pesticides. Its chemical properties make it a valuable component in the creation of effective and novel pest control agents.
Used in Research and Development:
4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER is also used as a research compound in various scientific studies. It aids researchers in understanding its properties and potential applications, thus contributing to the broader field of chemical research and development.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 823-96-1 Trimethylboroxine 
• 67-56-1 methanol 
• 1060805-95-9 4-chloro-6-methylnicotinic acid 
• 1005515-30-9 4‐chloro‐6‐methylpyridine‐3‐carbonyl chloride 
• 67367-33-3 4-hydroxy-6-methylnicotinic acid 
• 33821-58-8 6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 

Downstream Products

• 1315469-66-9 4-(4-bromo-2,5-dichloro-phenoxy)-6-methyl-nicotinic acid methyl ester 
• 1315469-24-9 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[4-(2,5-dichloro-phenoxy)-6-methyl-pyridin-3-yl]-methanone 
• 1315469-25-0 [4-(4-bromo-2,5-dichloro-phenoxy)-6-methyl-pyridin-3-yl]-(4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-methanone 
• 1315469-26-1 2,5-dichloro-4-[5-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-2-methyl-pyridin-4-yloxy]-benzoic acid methyl ester 
• 1315469-27-2 2,5-dichloro-4-[5-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-2-methyl-pyridin-4-yloxy]-benzoic acid 
• 1315469-63-6 lithium 4-(2,5-dichloro-phenoxy)-6-methyl-nicotinate 
• 1315469-65-8 4-(4-bromo-2,5-dichloro-phenoxy)-6-methyl-nicotinic acid 
• 1454914-31-8 (4-(4-chloro-2-fluorophenyl)-6-methylpyridin-3-yl) methanol 
• 1454914-30-7 methyl 4-(4-chloro-2-fluorophenyl)-6-methylnicotinate 
• 1616293-35-6 6-phenoxymethyl-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-36-7 2-methyl-6-phenoxymethyl-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-37-8 6-phenoxymethyl-2(R)-(1,2,2-trimethyl-propyl)-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-38-9 2-(4-fluorophenyl)-6-phenoxymethyl-3,4-dihydro-2H-[2,7]-naphthyridin-1-one 
• 1629239-91-3 4-chloro-6-phenoxymethyl-nicotinic acid methyl ester 

Relevant articles and documents

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

CONDENSED LACTAM DERIVATIVE

The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

Five-membered azole heterocyclic compound and its preparation method, pharmaceutical composition and use thereof

The present invention relates to a five-membered azole heterocycle compound represented by the following general formula (I), a preparation method of the five-membered azole heterocycle compound, a drug composition of the five-membered azole heterocycle compound, and a use of the five-membered azole heterocycle compound in preparation of drugs for prevention or treatment of TGR5-mediated diseases. The formula (I) is represented by the instruction.

ARYL ETHER-BASE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

ARYL LACTAM KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Aryl vinyllactam serinekinase inhibitor

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.